AlphAIalphai — Financial news for AI agents
yahoo.comAUG 117 min read$XTNT

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Xtant Medical Holdings reported Q2 2026 revenue headwinds tied to divestitures to Companion Spine and the end of certain license revenue. Biologics softness and amniotic membrane weakness persisted, while 17 new Dilon reps weighed on sales. Full-year 2026 guidance was cut to $99M-$103M; cash fell to $9.9M. Gross margin was 57.9%.

Original reporting
yahoo.com
Published Aug 11, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary — source image
Source · yahoo.com
Decision brief

The 30-second read

$XTNTBearishMed
01

Why it matters

Near-term risk is elevated due to reduced full-year revenue guidance and gross margin decline, but the call also outlines specific catalysts for Q3 and beyond: biologics growth acceleration after rep learning curves, and a shift to gross revenue recognition for HEMOBLAST as sales transition to Xtant agreements.

02

Market read

This is a guidance and margin driver update with identifiable product and contract-transition catalysts that can reprice expectations for Q3 biologics growth and HEMOBLAST revenue recognition.

03

What to watch

Gross margin decline is attributed to Q-Code license termination and production inefficiencies; traders may need to separate one-time transition effects from sustainable margin structure.

Relevance 7/10Novelty 6/10Timing: post Q2 earnings call, guidance update for 2026 and Q3 transition assumptions

Background

The piece summarizes Xtant’s Q2 2026 earnings call, focusing on revenue headwinds from divestitures and license changes, commercial execution from a new Dilon sales force integration, and product-specific drivers (biologics, amnio, Trivium Shaped, HEMOBLAST Bellows).

Company-level read

Ticker impact

$XTNTBearishMedium confidence
Context

Xtant cut full-year 2026 revenue guidance to $99M-$103M, citing biologics softness and amnio headwinds, plus HEMOBLAST transition timing.

Expected impact

Bias to downside or volatility until investors underwrite the Q3 biologics acceleration and HEMOBLAST gross transition.

Evidence & confidence

The article provides concrete guidance and margin drivers (loss of Q-Code license revenue, production inefficiencies) alongside specific catalysts (Trivium launch, HEMOBLAST gross recognition shift) that can change expectations over the next few quarters.

Market effects

Sector

Signals ongoing demand softness in regenerative medicine, especially amniotic membrane and legacy orthobiologics, while hemostasis expansion may diversify revenue.

Regional

None stated.

Global

None stated.

Counterpoint

What could challenge this read

The guidance reduction may be largely timing and accounting related (HEMOBLAST transition from Dilon to Xtant agreements), so reported softness could overstate underlying demand.

Key entities

  • company
    Xtant Medical Holdings, Inc.

    Subject of the earnings call summary, providing Q2 drivers, full-year 2026 guidance, and product transition assumptions.

  • counterparty
    Dilon Technologies

    Partner whose exclusivity fee was recorded as a one-time operating expense and whose distribution agreement is being integrated/transitioned.

  • counterparty
    Companion Spine

    Buyer of divested non-core assets referenced as a source of year-over-year revenue headwinds.

  • customer
    Cleveland Clinic

    Named as a high-value hospital system expected to be reached via HEMOBLAST Bellows.

  • customer
    Mass General

    Named as a high-value hospital system expected to be reached via HEMOBLAST Bellows.

Read at source← All news

Related articles

AUG 11
$XTNTHigh

Xtant Medical Holdings, Inc. (XTNT): Results of Operations and Financial Condition

Xtant Medical Holdings, Inc. (XTNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Xtant Medical Reports Second Quarter 2026 Financial Results Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor c

SEC EDGAR 8-K6 min
AUG 11
$ONONMedAI 8/10

On Holding Stock Plunges 16% as Americas Growth Suddenly Cools

On Holding (ONON) shares fell about 16% after Q2 results. The company reported sales of CHF850.3 million, up 13.5% year over year, but Americas revenue rose only 4.5% versus stronger growth elsewhere. On said DTC revenue rose 26% to CHF388.4 million, gross margin increased to 65.4%, and it expects low-20% constant-currency sales growth for 2024.

yahoo.com3 min
AUG 11
$VMed

Visa Inc. (V) vs. Mastercard Incorporated (MA): Same Strong Spending Story, Very Different Stock Reactions

Visa and Mastercard both reported profit and revenue beats on resilient spending and World Cup travel demand. Visa posted profit up 8% to $6.3B ($3.32/share) and revenue up 14% to $11.6B, but shares fell about 1% after announcing 2,600 job cuts and a $563M charge. Mastercard reported profit up 21% to $5.04/share and revenue up 14% to $9.3B, and shares rose over 3%.

insidermonkey.com6 min
AUG 11
$FWRGMedAI 8/10

First Watch (FWRG) Q2 2026 Earnings Call Transcript

First Watch Restaurant Group (FWRG) reported Q2 2026 revenue of $354.7 million, up 15.2% year over year, with same-restaurant sales up 3.4% and traffic down 0.4%. Adjusted EBITDA was $34.5 million (9.7% margin). The company raised 2026 guidance to 12.5% to 14% revenue growth and $133 million to $136 million adjusted EBITDA, and plans to self-fund organic growth from 2027.

fool.com6 min